Indolent Non-hodgkin Lymphoma
Conditions
Keywords
Follicular Lymphoma, Marginal Zone Lymphoma, Parsaclisib
Brief summary
A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
Detailed description
Patients will be recruited for 2 cohorts. Cohort A will recruit 58 RRFL subjects, and Cohort B will recruit 62 RRMZL subjects.
Interventions
DRUGIBI376
IBI376 20 mg po. once daily for 8 weeks ，followed by 2.5mg once daily
Sponsors
Innovent Biologics (Suzhou) Co. Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged 18 years or older. 2. Histologically confirmed, relapsed or refractory, follicular B-cell non-Hodgkin lymphoma (NHL) (FL) Grade 1, 2, and 3a or MZL. 3. Ineligible for hematopoietic stem cell transplant. 4. Definition of RRFL or RRMZL: Subjects should have received 2 or more prior therapies for FL/MZL included at least one regimen containing Rituximab. Subjects should be refractory to Rituximab or experienced disease progression after achieved remission or disease progression within 6 months since last therapy. 5. Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥ 1 lesion that measures \> 1.5 cm in the longest dimension and ≥ 1.0 cm in the longest perpendicular dimension as assessed by computed tomography (CT) or magnetic resonance imaging (MRI). 6. Subjects must be willing to undergo an incisional, excisional, or core needle lymph node or tissue biopsy or provide a lymph node or tissue biopsy from the most recent available archival tissue. 7. ECOG performance status 0 to 2. 8. Life expectancy ≥ 12 weeks. 9. Adequate hematologic, hepatic, and renal function. 10. Willingness to avoid pregnancy or fathering children.
Exclusion criteria
1 . Known histological transformation from indolent NHL to diffuse large B-cell lymphoma. 2\. History of central nervous system lymphoma (either primary or metastatic). 3\. Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan-PI3K inhibitor. 4\. Prior treatment with a Bruton's tyrosine kinase inhibitor (eg, ibrutinib). 5\. Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of study treatment administration. 6\. Active graft-versus-host disease. 7. Subjects positive for hepatitis B surface antigen or hepatitis B core antibody will be eligible if they are negative for HBV-DNA. Subjects positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | 2 years | To assess the efficacy of IBI376 in terms of objective response rate (ORR) in subjects with relapsed or refractory follicular lymphoma (FL)/Marginal lymphoma(MZL). Subjects will be evaluated for ORR by an IRC (Lugano criteria) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response Rate (CRR) | 2 years | To assess complete response rate (CRR) |
| Progression-free Survival (PFS) | 2 years | To assess progression-free survival (PFS) |
| Duration of Response (DOR) | 2 years | To assess the duration of response (DOR) |
| Best percentage change in target lesion size | 2 years | To assess best percentage change in target lesion size |
| Safety and tolerability of IBI376 measured by adverse events (AEs) | Baseline through 30-35 days after end of treatment, up to approximately 12 months per subject | Defined as any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment. |
| Overall Survival (OS) | 2 years | To assess overall survival (OS) |
Countries
China
Outcome results
None listed